SREBF2 and viral infectious disease: More recently, SREBP-2 was reported to be highly activated in COVID-19 patients’ PBMCs and contributed to the generation of cytokine storm, while SREBP2 inhibitor could suppress cytokine storm and prevent pulmonary damages in a virus infection mouse model [59].